Andrew Michael Beekman (Andrew M Beekman)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Molecular Docking

Structure Activity Relationship

Top Venues

Chemical communications (Cambridge, England)

Organic & biomolecular chemistry

RSC chemical biology

Chemical science

This page only lists publications with an associated author ORCID identifier.

Publications

Marco M D Cominetti, Zoë Rachael Goddard, Bethany R Hood, Andrew Michael Beekman, Maria A O'Connell, Mark Searcey
Borylation via iridium catalysed C-H activation: a new concise route to duocarmycin derivatives. Organic & biomolecular chemistry (2024)
Deanne Hayward, Zoë Rachael Goddard, Marco M D Cominetti, Mark Searcey, Andrew Michael Beekman
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction. Chemical communications (Cambridge, England) 60 (63) (2024)
Marco M D Cominetti, Zoë Rachael Goddard, Bethany R Hood, Andrew Michael Beekman, Maria A O'Connell, Mark Searcey
Borylation via iridium catalysed C-H activation: a new concise route to duocarmycin derivatives. Organic & biomolecular chemistry 22 (27) (2024)
Deanne Hayward, Zoë Rachael Goddard, Marco M D Cominetti, Mark Searcey, Andrew Michael Beekman
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction. Chemical communications (Cambridge, England) (2024)
Deanne Hayward, Zoë Rachael Goddard, Marco M D Cominetti, Mark Searcey, Andrew Michael Beekman
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction. Chemical communications (Cambridge, England) 60 (63) (2024)
Deanne Hayward, Zoë Rachael Goddard, Marco M D Cominetti, Mark Searcey, Andrew Michael Beekman
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction. Chemical communications (Cambridge, England) 60 (63) (2024)
Marco M D Cominetti, Zoë Rachael Goddard, Bethany R Hood, Andrew Michael Beekman, Maria A O'Connell, Mark Searcey
Borylation via iridium catalysed C-H activation: a new concise route to duocarmycin derivatives. Organic & biomolecular chemistry 22 (27) (2024)
Deanne Hayward, Andrew Michael Beekman
Strategies for converting turn-motif and cyclic peptides to small molecules for targeting protein-protein interactions. RSC chemical biology 5 (3) (2024)
Marco M D Cominetti, Zoë Rachael Goddard, Bethany R Hood, Andrew Michael Beekman, Maria A O'Connell, Mark Searcey
Borylation via iridium catalysed C-H activation: a new concise route to duocarmycin derivatives. Organic & biomolecular chemistry 22 (27) (2024)
Deanne Hayward, Andrew Michael Beekman
Strategies for converting turn-motif and cyclic peptides to small molecules for targeting protein-protein interactions. RSC chemical biology 5 (3) (2024)
Oliver Charles Cartwright, Andrew Michael Beekman, Marco M D Cominetti, David A Russell, Mark Searcey
A Peptide-Duocarmycin Conjugate Targeting the Thomsen-Friedenreich Antigen Has Potent and Selective Antitumor Activity. Bioconjugate chemistry 31 (7) (2020)
Lesley Ann Howell, Andrew Michael Beekman
In silico peptide-directed ligand design complements experimental peptide-directed binding for protein-protein interaction modulator discovery. RSC chemical biology 2 (1) (2020)
Zoë Rachael Goddard, Andrew Michael Beekman, Marco M D Cominetti, Maria A O'Connell, Isabelle Chambrier, Michael J Cook, María J Marín, David A Russell, Mark Searcey
Peptide directed phthalocyanine-gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancers. RSC medicinal chemistry 12 (2) (2020)
Andrew Michael Beekman, Marco M D Cominetti, Oliver Charles Cartwright, Dale L Boger, Mark Searcey
A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase. MedChemComm 10 (12) (2019)
Andrew Michael Beekman, Marco M D Cominetti, Samuel J Walpole, Saurabh Prabhu, Maria A O'Connell, Jesus Angulo, Mark Searcey
Identification of selective protein-protein interaction inhibitors using efficient in silico peptide-directed ligand design. Chemical science 10 (16) (2019)